A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/1999
12/22/1999	EP0965640A1 GP75 as a tumor vaccine for melanoma
12/22/1999	EP0965345A2 Use of acemannan
12/22/1999	EP0964925A2 A basal cell carcinoma tumor suppressor gene
12/22/1999	EP0964870A2 Lsr receptor, activity, cloning, and uses for diagnosing, preventing and/or treating obesity and related risks or complications
12/22/1999	EP0964869A1 Methods and compositions for generating angiostatin
12/22/1999	EP0964868A1 Isolated peptides derived from mage-2
12/22/1999	EP0964864A2 Pyrido 2,3-d] pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
12/22/1999	EP0964856A1 Bicyclic amino acids
12/22/1999	EP0964852A1 Indolecarboxylic compounds and their use as pharmaceutical compounds
12/22/1999	EP0964851A1 C-terminal ketone hydroxamic acid inhibitors of matrix metalloproteinases and tnfa secretion
12/22/1999	EP0964697A1 Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
12/22/1999	EP0964694A1 Mucin-mediated immunomodulation
12/22/1999	EP0964676A1 Microparticles and their use in cancer treatment
12/22/1999	EP0910385A4 Sensitization of cells to radiation and chemotherapy
12/22/1999	EP0876160B1 Ligand directed enzyme prodrug therapy
12/22/1999	EP0758312B1 Substituted fused and bridged bicyclic compounds as therapeutic agents
12/22/1999	EP0726954B1 Cytokine antagonists
12/22/1999	EP0515386B1 Glycoalkaloids
12/22/1999	CN1239479A Mage-1- encoding cDNA, tumor rejection antigen precursor mage-10, antibodies specific to molecule, and uses thereof
12/22/1999	CN1239431A Immunogenic TLP compsn.
12/22/1999	CN1239430A Treatment of highly vascular tumours
12/22/1999	CN1239429A Methods for minimizing bone loss
12/22/1999	CN1239097A Artemisine compounds, their preparing process and medicine composition containing them
12/22/1999	CN1238991A Sol preparation of rhenium nuclein labeled iodinated oil and its preparing process and application
12/21/1999	US6005117 Imino compounds, process for their preparation and their use as victronectin antagonists
12/21/1999	US6005099 For immunomodulators, antitumor agents, and components of vaccines with reduced endotoxicity
12/21/1999	US6005098 Nucleoside derivative which can be administered with 5-fluorouracil to enhance antitumor activity
12/21/1999	US6005095 Antisense agents; antitumor agents
12/21/1999	US6005083 Substituted metal chelating compounds for imaging and therapy
12/21/1999	US6005080 Nucleotide sequences and expression vectors encoding hu-b1.219 gene product; molecular probes designed from its nucleotide sequence may be useful for prenatal testing and cancer diagnosis
12/21/1999	US6005075 Purification; use in antitumor and/or antiviral treatment
12/21/1999	US6005002 Nitrogen mustard prodrugs with novel lipophilic protecting groups, and processes for their production
12/21/1999	US6004991 Compounds for cosmetics with enantiomorphs
12/21/1999	US6004987 Use of ligands which are specific for RXR receptors
12/21/1999	US6004978 Methods of treating cancer with aromatic nitro and nitroso compounds and their metabolites
12/21/1999	US6004953 Administering synergistic mixture of ascorbic acid and cobalt or iron phthalo- or naphthalocyanine complex; side effect reduction; anticarcinogenic agents; catalysis
12/21/1999	US6004931 Method for inhibiting growth hormone action
12/21/1999	US6004815 Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
12/21/1999	US6004803 Genes encoding HSV1-TK containing a deletion of 5' cryptic promoter sites, vectors and cell lines
12/21/1999	US6004792 Amino acid sequence of enzyme which controls intracellular lipids; for antiinflammatory/antiproliferative/ anticarcinogenic agents; diagnosis and prevention of autoimmune, gastrointestinal, and cardiovascular disorders
12/21/1999	US6004558 Administering extracts of leguminous plants from which the isoflavones genistein, daidzein, formononetin and biochanin and/or their glycosides have been removed
12/21/1999	US6004555 Methods for the specific coagulation of vasculature
12/21/1999	US6004554 Methods for targeting the vasculature of solid tumors
12/21/1999	US6004553 Inhibitors of tumor necrosis factor receptor associated factor-(traf) mediated signal transduction; use in screening assays and as pharmaceuticals
12/21/1999	US6004550 Intracellular expression of carboxypeptidase G2 in a nitrogen mustard prodrug system
12/21/1999	US6004535 Methods of imaging neoplastic disease and of detecting and quantifying MN protein/polypeptide using MN-specific antibodies
12/21/1999	US6004533 Radionuclide labeling of vitamin B12 and coenzymes thereof
12/21/1999	US6004529 Chelating agents
12/21/1999	CA2072891C Pseudomonas exotoxin fusion proteins having carboxyl alterations with increased cytotoxicity
12/21/1999	CA2044280C Vitamin d analogues
12/17/1999	CA2235420A1 Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
12/16/1999	WO1999065228A2 Pharmaceutical combination used to compensate for a testosterone deficiency while protecting the prostate
12/16/1999	WO1999064615A1 Formulations for electroporation
12/16/1999	WO1999064606A1 Tankyrase, a trfi binding protein
12/16/1999	WO1999064596A2 Proteins regulating gene expression
12/16/1999	WO1999064593A2 Cell cycle regulation proteins
12/16/1999	WO1999064589A1 Human receptor tyrosine kinase
12/16/1999	WO1999064588A1 TGFβ RII RECEPTOR NUCLEIC SEQUENCE, CODED PEPTIDE, AND USES
12/16/1999	WO1999064570A1 Novel methods and interferon deficient substrates for the propagation of viruses
12/16/1999	WO1999064464A2 Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means
12/16/1999	WO1999064461A2 Monoclonal antibodies, cross-reactive antibodies and method for producing the same
12/16/1999	WO1999064423A1 Furopyridine derivatives and their therapeutical use
12/16/1999	WO1999064420A1 β-CARBOLINE COMPOUNDS
12/16/1999	WO1999064413A1 Cinnamoyl distamycin analogous derivatives, process for their preparation, and their use as antitumor agents
12/16/1999	WO1999064401A2 Imidazolyl derivatives and their use as somatostatin receptor ligands
12/16/1999	WO1999064400A1 INHIBITORS OF p38
12/16/1999	WO1999064393A1 Novel antiestrogens, a method for the production thereof, and their pharmaceutical application
12/16/1999	WO1999064068A1 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
12/16/1999	WO1999064065A2 Tumour therapy and imaging
12/16/1999	WO1999064039A1 Bradykinin antagonists
12/16/1999	WO1999064029A1 Plant extract
12/16/1999	WO1999064021A1 hCEPR RECEPTOR
12/16/1999	WO1999064013A1 Pharmaceutical composition with tumor necrosis factor a and 2-methoxyestrone-3-o-sulphamate for inhibition of estrone sulphatase
12/16/1999	WO1999063998A1 Novel use of hiv protease inhibiting compounds
12/16/1999	WO1999063987A1 N-acetyl 3-chloroprocainamide, acid addition salts thereof, and methods of use
12/16/1999	WO1999063980A1 Treatment of anti-estrogen resistant breast cancer using rxr modulators
12/16/1999	WO1999063975A2 A method for stimulating the immune system
12/16/1999	WO1999063974A2 Selective estrogen receptor modulator in combination with denydroepiandrosterone (dhea) or analogues
12/16/1999	WO1999063973A2 PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL
12/16/1999	WO1999063945A2 Vaccination strategy to prevent and treat cancers
12/16/1999	WO1999063942A2 Isolation and structural elucidation of the human cancer cell growth inhibitory compound denominated 'agelagalastatin'
12/16/1999	WO1999063931A2 Peptidyl-prolyl cis-trans isomerase inhibitors and uses therefor
12/16/1999	WO1999063828A1 Broad specificity dna damage endonuclease
12/16/1999	WO1999057292A9 Genomic sequences upstream of the coding region of the ifn-alpha2 gene for protein production and delivery
12/16/1999	WO1999052546A3 A method of inducing an anti-tumor response against a lung metastasis in a melanoma patient
12/16/1999	WO1999052543A3 Pharmaceutical compositions comprising erythropoietin for treatment of cancer
12/16/1999	WO1999043807A3 Human channel-related molecules
12/16/1999	WO1999041375A3 Human receptor proteins
12/16/1999	WO1999041373A3 Human transport-associated molecules
12/16/1999	WO1999041368A3 Optimization of immunomodulatory properties of genetic vaccines
12/16/1999	WO1999006540A3 Inhibitors of cell-cycle progression and uses related thereto
12/16/1999	WO1998024902A8 Adaptor protein frs2 and related products and methods
12/16/1999	DE19826213A1 Neue Antiestrogene, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung New antiestrogens, processes for their preparation and their pharmaceutical use
12/16/1999	CA2768882A1 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
12/16/1999	CA2768841A1 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
12/16/1999	CA2768828A1 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
12/16/1999	CA2768773A1 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
12/16/1999	CA2768682A1 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
12/16/1999	CA2335339A1 .beta.-carboline compounds
12/16/1999	CA2334990A1 Novel use of hiv protease inhibiting compounds

1 ... 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 ... 2211